SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research’s report, “ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported.” The developments have prompted national shareholders rights firm Hagens Berman to investigate whether ADMA may have violated the federal securities laws. The firm urges ...

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud Share NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLPis investigating potential claims against ADMA Biologics, Inc. ("ADMA†or the "Company†) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal se ...

New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning potential violations of the federal securities laws.On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth." Culper Research's short report contends ASCENIV only achieved its growth on the back of "classic channel stu ...

Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines Highlights that Demand for – and Utilization of – ASCENIV Has Grown Steadily Over Past Two Years and is at Record High Details that Stocking Levels Maintained by ADMA’s Distributors Align with Industry Standards and Reflect the Long Production Cycle for ASCENIV RAMSEY, N.J. a ...

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit. Why is ADMA Biologics Being Investigated for Securities Fraud? ADMA Biologics is an end-to-end commercial biopharmaceutic ...

ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law Mar 26, 2026 2:34 PM Eastern Daylight Time ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law Share NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLPannounces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violati ...

Core Insights - ADMA Biologics reported a total revenue of $510 million for FY 2025, reflecting a 20% year-over-year growth, primarily driven by increased sales of ASCENIV [1][9] - ASCENIV revenue reached $363 million, marking a significant 51% year-over-year increase, indicating strong demand and adoption in the market [1][42] - The company achieved an adjusted net income of $161 million, representing a 35% year-over-year growth, and an adjusted EBITDA of $231 million, which is a 40% increase from the previous year [1][14] Financial Performance - Total revenue for FY 2025 was $510.2 million, up from $426.5 million in FY 2024, an increase of $83.7 million or 20% [9] - Gross profit for FY 2025 was $292.8 million, resulting in a gross margin of 57.4%, compared to 51.5% in FY 2024 [10] - Adjusted net income for FY 2025 was $160.8 million, compared to $119.2 million in FY 2024, representing a growth of 35% [13] - Adjusted EBITDA for FY 2025 was $231 million, up from $164.6 million in FY 2024, reflecting a 40% increase [14] Strategic Developments - The appointment of a new CFO is expected to enhance financial strategy, working capital execution, and capital allocation discipline [1][5] - The company is advancing its SG-001 pipeline program with an anticipated FDA pre-IND meeting in 2026, which may lead to a registrational trial [1][17] - Ongoing share repurchases and a focus on capital structure are aimed at increasing stockholder value [1] Future Guidance - For FY 2026, total revenue is expected to exceed $635 million, with adjusted net income anticipated to exceed $255 million and adjusted EBITDA expected to exceed $360 million [6] - FY 2027 total revenue is projected to exceed $775 million, with adjusted net income expected to exceed $315 million and adjusted EBITDA anticipated to exceed $455 million [6] - The company is targeting over $1.1 billion in total annual revenue by FY 2029, translating to at least $700 million in adjusted EBITDA [6]

Company Overview - ADMA Biologics is a specialty producer of unique plasma-derived biologic products, primarily focusing on IVIG products that extract antibodies from human plasma [3] - The company has three FDA-approved commercial products and has preannounced total revenue of over $510 million for its commercial organization [3] Financial Performance - For the fourth quarter, ADMA expects revenue to exceed $139 million, with EBITDA projected at $77 million to $78 million or more, and net income anticipated to be around $50 million or more [3] - This financial performance represents a substantial increase compared to the third quarter of 2025 [3] Intellectual Property - The company holds intellectual property that protects its lead product ASCENIV until June 2035, focusing on the testing and identification processes [4]

ADMA Biologics Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology January 2026 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, "we," "our" or the "Company"), including, without limitation, statements that may predict, forecast, indicate, or imply future results, performan ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $134.2 million, reflecting a 10% increase quarter-over-quarter and a 12% increase year-over-year [5][11] - GAAP net income reached $36.4 million, up 6% quarter-over-quarter and 1% year-over-year [5][11] - Adjusted EBITDA grew to $58.7 million, representing a 16% quarter-over-quarter increase and a 29% year-over-year increase [5][11] Business Line Data and Key Metrics Changes - ASCENIV, the company's specialty immunoglobulin product, showed record utilization driven by strong prescriber adoption and sustained patient demand [6][10] - Product-level gross margins reached 63.7% during Q3 2025, excluding a plasma sale of $13.8 million [11][12] - The company completed a sale of approximately $13.8 million of normal-source plasma at a negative margin contribution to optimize working capital [13] Market Data and Key Metrics Changes - The company anticipates improved ASCENIV reimbursement access beginning in 2026, with payer negotiations progressing positively [6][10] - A retrospective cohort analysis showed a significant reduction in infection rates for patients switching from standard IG therapy to ASCENIV, with a reduction of over 50% [7][26] Company Strategy and Development Direction - The company aims to expand ASCENIV access and utilization, scale yield-enhanced production, and drive continued margin expansion [10][19] - The SG-001 program is progressing, with potential to address significant unmet medical needs and expected to contribute to long-term revenue growth [9][19] - The company maintains a disciplined capital allocation strategy, focusing on stockholder value through share repurchases and reinvestment in growth initiatives [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $1.1 billion in annual revenue by 2029, supported by yield-enhancement efficiencies and expanding ASCENIV demand [14][15] - The company expects continued strong double-digit revenue growth into 2026, driven by improved payer access and increased utilization of ASCENIV [17][31] Other Important Information - The company maintains a strong balance sheet with an undrawn $225 million revolving credit facility, providing flexibility for growth initiatives [10][14] - The FDA's release of yield-enhanced production batches is expected to improve gross margins starting in Q4 2025 [8][52] Q&A Session Summary Question: Can you provide details on the publication of ASCENIV data? - Management confirmed plans for a peer-reviewed publication in early 2026, highlighting significant infection reduction data [24][26] Question: What is the expected impact of ASCENIV data on demand? - Management anticipates that the data will reinforce prescriber confidence and potentially lead to earlier use of ASCENIV in treatment cycles [29][31] Question: What factors contributed to raising revenue guidance? - Management cited record product pull-through and increased availability of ASCENIV as key factors for confidence in raised guidance [35][36] Question: Are there any gating factors for yield-enhanced product impact in Q4? - Management indicated that yield-enhanced products will flow through product sales in Q4 without significant gating factors [41] Question: How will gross margins expand in the coming quarters? - Management expects gross margins to potentially exceed 70% in 2026 due to ongoing yield enhancements and product mix shifts [52] Question: What is the status of payer negotiations for ASCENIV? - Management reported positive negotiations with payers, with expectations for improved access and reduced restrictions in 2026 [54][58] Question: How many physicians or centers are currently using ASCENIV? - Management noted that there are over 100 prescribing physicians, with a target of reaching around 300 to support revenue goals [60][62] Question: Can the hit rate for plasma collections improve over time? - Management expressed optimism that the amount of high-titer plasma collected will grow, supported by strong relationships with third-party suppliers [68]